2024
A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Magenau J, Jaglowski S, Uberti J, Farag S, Riwes M, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang M, Burns L, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood 2024, 143: 21-31. PMID: 37647633, PMCID: PMC10934299, DOI: 10.1182/blood.2023020250.Peer-Reviewed Original ResearchConceptsAcute graft-versus-host diseaseGraft-versus-host diseaseHematopoietic stem cell transplantationDose-limiting toxicityMUD hematopoietic stem cell transplantationGVHD-free survivalMultidose regimenMyeloablative conditioningHematologic malignanciesHuman leukocyte antigen-matched unrelated donorsPrevention of graft-versus-host diseaseAllogeneic hematopoietic stem cell transplantationCalcineurin inhibitor-based prophylaxisMatched controlsDose-escalation phaseSingle-dose regimensStem cell transplantationPhase 2 trialSustained drug exposureAssociated with higher ratesDamage-associated molecular patternsExpansion cohortDouble-blindPlacebo-controlledUnrelated donor
2023
CD24-Siglec interactions in inflammatory diseases
Liu Y, Zheng P. CD24-Siglec interactions in inflammatory diseases. Frontiers In Immunology 2023, 14: 1174789. PMID: 37228622, PMCID: PMC10203428, DOI: 10.3389/fimmu.2023.1174789.Peer-Reviewed Original ResearchConceptsMultiple cell typesDifferential glycosylationRegulation of inflammatory diseasesBiological significanceSurface CD24Treat graft-vs-host diseaseMetabolic disordersInflammatory diseasesGraft-vs-host diseaseCell typesPhysiological functionsInflammatory response to tissue injurySiglecsResponse to tissue injuryRespiratory distressAutoimmune diseasesCD24Tissue injuryEndogenous ligandClinical translationGlycosylationDiseaseTranslational research